NBS: Vanquishes Disease Through Stem Cell Therapy
Cardiovascular disease costs over $445 billion today and is projected to grow to $1 trillion by 2030 according to the American Heart Association. Stem cell research aims to make a significant and positive impact on this number one killer in America. NeoStem Inc. (NBS) is a stem cell company taking a multi-pronged approach to stem cell research and is on track to be the huge winner in the coming stem cell age.
NBS is involved in the manufacture of cell therapy-based treatments. It also provides contract development and manufacturing services to other members of the regenerative medicine field, including adult stem cell collection and storage services.